Na Zhang

机构：First Hospital of China Medical University, Beijing Hospital of Traditional Chinese Medicine, China Medical University · ORCID：0000-0001-6978-2731

发表论文 92 篇 · 总被引 2146 次 · h-index 26

代表论文

• Irisin alleviates hepatic steatosis by activating the autophagic SIRT3 pathway (2025 · Chinese Medical Journal · 被引 10)
• Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time (2022 · Frontiers in Immunology · 被引 10)
• Evolution and Discovery of Matrine Derivatives as a New Class of Anti-Hepatic Fibrosis Agents Targeting Ewing Sarcoma Breakpoint Region 1 (EWSR1) (2023 · Journal of Medicinal Chemistry · 被引 7)
• Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial (2024 · Renal Failure · 被引 6)
• Construction of a Prediction Model for Adverse Perinatal Outcomes in Foetal Growth Restriction Based on a Machine Learning Algorithm: A Retrospective Study (2025 · BJOG An International Journal of Obstetrics & Gynaecology · 被引 5)
• Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR Pathway in Hepatic Steatosis (2025 · Journal of Gastroenterology and Hepatology · 被引 5)